Status:
TERMINATED
Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Lead Sponsor:
EMD Serono
Collaborating Sponsors:
Merck KGaA, Darmstadt, Germany
Ono Pharmaceutical Co. Ltd
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
The objective of this active-drug Extension Study is to evaluate the continuing safety and efficacy of ONO-4641 (MSC2430913A) in subjects with relapsing-remitting multiple sclerosis (RRMS) who have co...
Eligibility Criteria
Inclusion
- Completed 26 weeks of double-blind phase of Study ONO-4641POU006
Exclusion
- Presence of any dermatological abnormalities during Study ONO-4641POU006 that could increase the risk of the patient developing a skin cancer
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2015
Estimated Enrollment :
340 Patients enrolled
Trial Details
Trial ID
NCT01226745
Start Date
October 1 2010
End Date
January 1 2015
Last Update
July 12 2016
Active Locations (70)
Enter a location and click search to find clinical trials sorted by distance.
1
Tucson Clinical Site 133
Tucson, Arizona, United States, 85705
2
Aurora Clinical Site 132
Aurora, Colorado, United States, 80045
3
Fort Collins Clinical Site 123
Fort Collins, Colorado, United States, 80528
4
Fairfield Clinical Site 110
Fairfield, Connecticut, United States, 06824